MPN Clinical Trials

Clinical trials are an important step in the process of discovering new treatments for MPNs. The decision to participate in a clinical trial is one you should carefully consider. It is important to discuss clinical trial participation with your family and your physician. We've compiled a FAQ to assist patients who are considering participating in a clinical trial.

The MPN Research Foundation has complied a list of trials, some of which are currently recruiting patients:

If you are a company or investigator who is running a trial and you need to make a change to the listing for your trial contact our office at 773-453-9917 or by sending an email.

Find a Clinical Trial

Click the boxes below to filter clinical trials by disease type.

Myelofibrosis (MF)
Essential Thrombocythemia (ET)
Polycythemia Vera (PV)


This is a multi-center, open label study testing the long-term safety, tolerability and efficacy of Givinostat in patients with Polycythemia Vera, Essential Thrombocythemia, primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis following core protocols in chronic myeloproliferative neoplasms and/or patient-named compassionate use program.

Read the full description here.


Navitoclax + Ruxolitinib

A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis.

The purpose of this study is to evaluate the addition of navitoclax to ruxolitinib in patients who have been receiving ruxolitinib alone. Ruxolitinib treatment alone has not been fully controlling disease but preclinical data suggests that the combination of navitoclax with ruxolitinib may help to overcome disease resistance to ruxolitinib.

Click here for more information.



Pembrolizumab also known as Keytruda is a drug that has recently been approved in the United Stated by the Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma and disease progression. Pembrolizumab is experimental in the treatment of MPN. The researchers want to find out what effects, good and /or bad it has on participants and the disease.

Oral Rigosertib

The goal of this clinical research study is to learn if rigosertib can help to control MF in patients with anemia. This trial is being conducted at MD Anderson Call 713-794-5783 for more information.

CPI-0610 +/- Ruxolitinib

CPI-0610 +/- Ruxolitinib A Phase 2 study of CPI-0610 alone or in combination with ruxolitinib in patients with myelofibrosis. This study is for MF patients who are currently taking ruxolitinib but have a sub-optimal response or for patients who are resistant, intolerant or have lost response to a JAK inhibitor. For more information about the study click here or click here for more information about CPI-0610 and Constellation Pharmaceuticals.

Selumetinib combined with Azacitidine

Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia


This is a Phase 1 open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with myelofibrosis. Click here for more information.

Idasanutlin | NCT0328724

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera. For More Trail Information:


Navitoclax 9/5/2017

A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis. The trial is for patients who have been receiving ruxolitinib for 6 months. Details are available at the clinical website To find a site, patients can contact AbbVie at  847.283.8955 or at


PAC203 | Pacritinib | Posted 6/26/17

CTI Biopharma is recruiting patients for the PAC203 study, a randomized phase 2 trial evaluating different doses of pacritinb in myelofibrosis patients regardless of platelet count and who have previously received ruxolitinib (Jakafi/Jakavi). Please see the link below for more information.

Click here for more information about PAC203


Luspatercept | Posted 7/13/2017

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence.

For more information, please refer to NCT03194542 on

Or Click here for more information.



RESET-272 | Posted 6/15/2017

A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)


Ruxolitinib + Thalidomide

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis


INCB050465 | Posted 6/15/2017

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis.Click here for trial information. 



Ruxolitinib - Ruxo-BEAT trial

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia (Ruxo-BEAT) Click here for trail information.


TGR-1202 + Ruxolitinib

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea. Click here for more information. 


Ruxolitinib vs BAT in High Risk ET

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line.  Click here for trial information. 


Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC)



The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies. For more information contact: John Gerecitano, MD, PhD 212-639-3748 OR Shanu Modi, MD 646-888-5243


A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/ Myeloproliferative Neoplasms, and Myelofibrosis. For more information contact Debbie Johnson at



Open Label Study of Single Agent Oral RG7388

Sponsor: John Mascerenhas

Contact: John Mascarenhas, MD at (212) 241-3417 or

Jill Kleczko at (212)241-0573 or



Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Contact: Dr. Ronald Hoffman at or 212-241-2296


* Familial Study of MPDs

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

Contact: Dr. Josef Prchal at 801-581-4220 or Kim Hickman at 801-581-3707


* AOP2014 and Hydroxyurea

Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PROUD-PV)

Contact: Michael Zoerer at 43+1+5037244-46 , OR


Pegylated Interferon

AOP2014 in patients with Polycythemia Vera who previously participated in the PROUD-PV study

Contact: Michael Zoerer at / 43+1+5037244-46 OR check



Phase I/II trial of SL-401 in patients with advanced, high risk MPNs, including MF, CMML, advanced systemic mastocytosis and HES/CEL

Contact: Srdan Verstovsek, MD, PhD at 713-745-3429


Research Tissue Bank

Study allows for the preservation and storage of a small portion of tissues to be used for the study of MPDs.

Contact: Rona S. Weinberg, PhD at 212-570-3412 OR


Correlative Bio-Marker Study

Correlative Biomarker Study in Patients with Myeloproliferative Disorders

Contact: Rona S. Weinberg, PhD at 212-570-3412 OR

Ronald Hoffman, MD at 212-241-2297 OR


Sotatercept (ACE-011)

Phase II, open-label study of sotatercept (ACE-011) in subjects with MF & significant anemia

Contact: Srdan Verstovsek, MD, PhD, at 713-745-3429



A Phase 1 Dose Escalation Study of TAK-901 in Subjects with Advanced Hematological Malignancies

Contact: Millennium Medical or Drug Info Center at 877-674-3784 OR


Ruxolitinib & Pracinostat

Evaluation of Ruxolitinib & Pracinostat Combination as a therapy for Patients with Myelofibrosis

Contact: Srdan Verstovsek, MD, PhD at 713-745-3429



INC424 for Patients with Myelofibrosis (JUMP)

Contact: Novartis Pharmaceuticals at +1-862-778-8300


* NS-018

Safety and Tolerability Study of Oral NS-018 in Patients with Myelofibrosis (MF) previously treated with a Janus Kinase Inhibitor,

( more information, contact Tomonori Uno of NS Pharma at:


Oral Arsenic

Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults with Myelofibrosis

Contact: Roswell Park Cancer Center Institute at 877-275-7724 or


* LCL-161

Phase 2 LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Contact: Naveen Pemmaraju, MD at 713-792-4956



Study of Pomalidomide in Persons with Myelofibrosis (RESUME)

Contact: Mary Bartlett at 913-266-0513 or

Alyce Kay at 913-266-0369 or


Ruxolitinib & Panobinostst

Panobinostat and Ruxolitinib in myelofibrosis (Prime Study) - Phase I/II study of combination oral JAK2 tyrosine kinase inhibotor (JAK2-TKI) and histone deacetylase inhibitor (HDACI) therapy in patients with myelofibrosis

Contact: Jill Kleczko at or

John Mascarenhas at


Ruxolitinib & LDE225

A Phase1b/11 Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Contact: Novartis at 41-61-3241111


Ruxolitinib & SCT

Exploring the potential of dual kinase JAK1/2 inhibitor Ruxolitinib (INC424) with reduced intensity allogenic hematopoeitic stem cell transplantation in patients with myelofibrosis (MPD-RC #114)

Contact: Jill Kleczko at,

Vikas Gupta at 416-946-4521,

Adam Mead at OR 44-0-1865-222325, or

John Mascarenhas at



A Phase 2, Prospective Study of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)

More information is available at or please contact:


P1101 Ropeginterferon Alpha-2b | Updated 6/26/2017

This pilot phase II trial studies P1101 (polyethyleneglycol [PEG]-proline-interferon alpha-2b) in treating patients with early myelofibrosis. PEG-proline-interferon alpha-2b is a substance that can improve the body's natural response and may slow the growth of early myelofibrosis. More information available here:

Contact: Allison Rosenthal at


Ruxolitinib with Allogeneic Hematopoeitic Cell Transplantation

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis.

Contact: Sara Duffey, Clinical Research and Education Specialist , Robert H. Lurie Comprehensive Cancer Center at 312.695.1102 or


Alisertib (MLN8237)

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinases, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelofibrosis)

For more information about this study please contact us at: 312.472.123 or at



PF-04449913 Single-Agent In Patients With Myelofibrosis Previously Treated With a Janus Kinase Inhibitor

Pfizer Clinical Trial Call Center: 1-800-718-1021 or contact us here



Get free, timely information on living with an MPN.